Inflammation and disease activity in first year boost ACS risk. In patients with new-onset rheumatoid arthritis (RA) early disease control and other measures are essential to curb comorbid conditions that boost the risk of cardiovascular disease (CVD) and coronary events
Patients with refractory rheumatoid arthritis (RA) who were treated with rituximab (Rituxan) showed improvements on multiple patient-reported outcomes, according to a report from a large U.S. registry.
Danish matched cohort study has found a 1-year mortality rate of almost 14% in rheumatoid arthritis (RA) patients with interstitial lung disease (ILD) versus about 4% for RA patients with no ILD, rising to rates of 39% versus 18%, respectively, at 5 years, highlighting the need for early identification of the lung disorder.
Eating fish — tuna, salmon, sardines, trout, sole, halibut, poke, and grouper — may help reduce joint pain and inflammation in rheumatoid arthritis (RA) patients.
Early rheumatoid arthritis (RA) patients have significantly impaired grip strength 5 years after diagnosis, which might be helped by assessing hand function and prescribing rehabilitation in clinical settings.
Patient satisfaction with therapy depends upon decreases in pain and fatigue. These factors can strongly influence whether patients with rheumatoid arthritis who show objective clinical responses to treatment at 1 year also report subjective improvements in their health.
The risk of acute coronary syndrome (ACS) in patients with new-onset rheumatoid arthritis (RA) remains higher than that of the general population.
Standard treatment for rheumatoid arthritis (RA)—methotrexate and glucocorticoids—successfully improves clinical symptoms for most patients. Research by Ilaria Buondonno, PhD, and colleagues at the University of Torino, Italy, has revealed that the combination of a single dose of cholecalcipherol (300,000 IU) with standard treatment may go even further to improve the general health of patients with RA at three months relative to patients receiving standard therapy alone. The investigators published the results of their research, which evaluated patients at the very beginning of RA disease, online June 5 in PLoS One. Their intention was to investigate the early immunological alterations in patients with RA.